BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28404963)

  • 21. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma.
    Kim SS; Nam JS; Cho HJ; Won JH; Kim JW; Ji JH; Yang MJ; Park JH; Noh CK; Shin SJ; Lee KM; Cho SW; Cheong JY
    J Gastroenterol Hepatol; 2017 Jan; 32(1):199-207. PubMed ID: 27194671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
    Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.
    Gao HJ; Zhao MC; Zhang YJ; Zhou DS; Xu L; Li GB; Chen MS; Liu J
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1151-62. PubMed ID: 25446815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.
    Zhang DZ; Wei XD; Wang XP
    World J Gastroenterol; 2015 Apr; 21(15):4635-43. PubMed ID: 25914473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early treatment response to transcatheter arterial chemoembolization is associated with time to the development of extrahepatic metastasis and overall survival in intermediate-stage hepatocellular carcinoma.
    Lee SW; Lee HL; Han NI; Jang JW; Bae SH; Choi JY; Yoon SK
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):81-88. PubMed ID: 27913882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of Benefit of Transcatheter Arterial Chemoembolization (TACE) in Patients with Resectable Solitary Hepatocellular Carcinoma.
    Ha TY; Hwang S; Lee YJ; Kim KH; Ko GY; Ii Gwon D; Ahn CS; Moon DB; Song GW; Jung DH; Lee HC; Lim YS; Kim KM; Shim JH; Choi JH; Lee SG
    World J Surg; 2016 May; 40(5):1200-10. PubMed ID: 26666422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma.
    Wang JH; Zhong XP; Zhang YF; Wu XL; Li SH; Jian PE; Ling YH; Shi M; Chen MS; Wei W; Guo RP
    Cell Death Dis; 2017 Sep; 8(9):e3043. PubMed ID: 28880268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
    Takayasu K; Arii S; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M
    J Hepatol; 2012 Apr; 56(4):886-92. PubMed ID: 22173160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcatheter arterial chemoembolization (TACE) for lymph node metastases in patients with hepatocellular carcinoma.
    Wu H; Liu S; Zheng J; Ji G; Han J; Xie Y
    J Surg Oncol; 2015 Sep; 112(4):372-6. PubMed ID: 26368066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study.
    Chen J; Lai L; Lin Q; Huang W; Cai M; Zhu K; Huang M
    Oncotarget; 2017 Jan; 8(1):408-417. PubMed ID: 27880724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
    Han K; Kim JH
    World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.
    Pinato DJ; Sharma R
    Transl Res; 2012 Aug; 160(2):146-52. PubMed ID: 22677364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study.
    Lee HS; Kim JS; Choi IJ; Chung JW; Park JH; Kim CY
    Cancer; 1997 Jun; 79(11):2087-94. PubMed ID: 9179054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic Variants in ASCT2 Gene are Associated with the Prognosis of Transarterial Chemoembolisation-Treated Early- Stage Hepatocelluar Carcinoma.
    Ge NJ; Shi ZY; Yu XH; Huang XJ; Wu YS; Chen YY; Zhang J; Yang YF
    Asian Pac J Cancer Prev; 2015; 16(9):4103-7. PubMed ID: 25987094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function.
    Hsu KF; Chu CH; Chan DC; Yu JC; Shih ML; Hsieh HF; Hsieh TY; Yu CY; Hsieh CB
    Eur J Radiol; 2012 Mar; 81(3):466-71. PubMed ID: 21376495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
    Shin BS; Park MH; Jeon GS
    Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.
    Sergio A; Cristofori C; Cardin R; Pivetta G; Ragazzi R; Baldan A; Girardi L; Cillo U; Burra P; Giacomin A; Farinati F
    Am J Gastroenterol; 2008 Apr; 103(4):914-21. PubMed ID: 18177453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Single center experience over a 5-year period with sequential transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC)].
    Herber SC; Otto G; Woerns M; Moench C; Kanzler S; Junginger T; Schneider J; Schuchmann M; Kummer I; Manzl N; Düber C; Pitton MB
    Rofo; 2007 Mar; 179(3):289-99. PubMed ID: 17325996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.